I acknowledge that the information on this site is for non-US customers only. The site may contain information that is not approved for your country.

Skip to content

For investors
Customer support
Webstore
Document portal

Diagnostic areas
Products
Services
Resources
About us

Contact us

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Post-transplantation
Devyser HLA Loss
One Lambda Devyser Accept cfDNA
One Lambda Devyser Chimerism NGS

Thalassemia
Devyser Thalassemia NGS
Devyser Thalassemia v2

Hereditary cancer
Devyser BRCA NGS
Devyser HBOC NGS
Devyser BRCA PALB2 NGS
Devyser LynchFAP

Fetal RHD screening NIPT
Devyser RHD

Transfusion medicine
Devyser Genomic Blood Typing

Cystic fibrosis
Devyser CFTR
Devyser CFTR Core
Devyser CFTR 68
Devyser CFTR Italia

Cardiovascular diseases
Devyser Thrombophilia
Devyser FH NGS
Devyser HFE
Devyser CVD

Male infertility
Devyser AZF Extension
Devyser AZF v2

Rapid aneuploidy analysis
Devyser Compact
Devyser Complete
Devyser Extend M1
Devyser Resolution 13
Devyser Resolution 18
Devyser Resolution 21
Devyser Resolution XY

Software
Advyser Solid organs
Advyser Chimerism
Amplicon Suite

Cybergene ChromoQuant®
Prenatal diagnostics
Pregnancy loss diagnostics
Male infertility diagnostics

Accessories
560 sizer orange
DEV-5 Dye set
Devyser Index plate A
Devyser Index plate LB-A
Devyser library clean
Devyser Index Plate LB-192

Devyser Genomic Laboratories

Events & webinars
IVDR
Knowledge hub
Whitepapers
Devyser blog
Frequently asked questions (FAQs)
Calculator for chimerism
Sequence coverage calculator

Our company
Investors
Distributors
News and press
Career
Sustainability
Contact us

Diagnostic areas

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Products

Post-transplantation
Thalassemia
- Devyser Thalassemia NGS
- Devyser Thalassemia v2
Hereditary cancer
Fetal RHD screening NIPT
- Devyser RHD
Transfusion medicine
- Devyser Genomic Blood Typing
Cystic fibrosis
Cardiovascular diseases
Male infertility
- Devyser AZF Extension
- Devyser AZF v2
Rapid aneuploidy analysis
Software
Cybergene ChromoQuant®
Accessories

Services

Devyser Genomic Laboratories

Resources

Events & webinars
IVDR
Knowledge hub
Whitepapers
Devyser blog
Frequently asked questions (FAQs)
Calculator for chimerism
Sequence coverage calculator

About us

Our company
Investors
Distributors
News and press
Career
Sustainability
Contact us

For investors
Customer support
Webstore
Document portal

The Devyser blog

Fetal RHD screening NIPT | May 19, 2026

Noninvasive fetal RHD testing is emerging as a standard of care: insights from a global survey

Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and newborn (HDFN) and occurs due to incompatibility between an RhD-negative mother and an RhD-positive...

Find out more

Filter

Fetal RHD screening NIPT

Smarter prophylaxis: How RHD testing protects patients and resources

The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...

Top performance at high-throughput: Devyser RHD maintains high sensitivity within an automated, high-throughput setting in Sahlgrenska University Hospital Study

Over the past decade, there has been a wealth of research investigating the ideal approach to RHD...

Approval of Devyser’s RHD product in Canada

Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...

Devyser’s clinical laboratory in Atlanta receives CLIA certification

Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...

Literature review - NIPT for fetal RHD status using an exon 4-based assay

Early non-invasive prenatal testing (NIPT) for fetal Rhesus D (RHD) status is playing an...

Prevent RhD disease without overtreatment: how NIPT optimizes administration

Non-invasive prenatal testing (NIPT) can help us determine fetal RhD status without a drop of fetal...

RHD screening just got easier: how single exon NIPT testing helps

In RhD-negative mothers, anti-D prophylaxis can be withheld if the fetus is also RhD-negative....

Diagnostic areas

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Products and services

Kits and reagents
Our services

Resources

Events & webinars
Knowledge hub
Whitepapers
Devyser blog
Calculator for Chimerism
Sequence coverage calculator
IFUs and certificates

About us

Our company
Contact us
Distributors
News and press
Career
Whistleblowing policy
Sustainability

Investors

Press releases
Reports

© Devyser 2026

Privacy policy | Legal terms | About cookies